Stroke prevention in nonvalvular atrial fibrillation.
作者信息
Ganjehei Leila, Massumi Ali, Razavi Mehdi, Rasekh Abdi
机构信息
Department of Cardiology, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX 77030, USA.
出版信息
Tex Heart Inst J. 2011;38(4):350-2.
Abstract
摘要
相似文献
1
Stroke prevention in nonvalvular atrial fibrillation.
Tex Heart Inst J. 2011;38(4):350-2.
2
Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
J Am Heart Assoc. 2014 Sep 16;3(5):e001031. doi: 10.1161/JAHA.114.001031.
3
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Circulation. 2014 Oct 21;130(17):1505-14. doi: 10.1161/CIRCULATIONAHA.114.008139.
4
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
Clin Cardiol. 2013 May;36(5):280-5. doi: 10.1002/clc.22112. Epub 2013 Mar 14.
5
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6.
6
Dabigatran for stroke prevention in all patients with atrial fibrillation?
Pharmacotherapy. 2011 Aug;31(8):725-8. doi: 10.1592/phco.31.8.725.
7
Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Circulation. 2013 Jun 18;127(24):2414-23. doi: 10.1161/CIRCULATIONAHA.112.000920. Epub 2013 May 22.
8
New agents to prevent strokes in nonvalvular atrial fibrillation.
Methodist Debakey Cardiovasc J. 2012 Jul-Sep;8(3):44-6. doi: 10.14797/mdcj-8-3-44.
9
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Circulation. 2011 Jan 18;123(2):131-6. doi: 10.1161/CIRCULATIONAHA.110.977546. Epub 2011 Jan 3.
10
Atrial fibrillation in 2010: advances in treatment and management.
Nat Rev Cardiol. 2011 Feb;8(2):67-8. doi: 10.1038/nrcardio.2010.206.
引用本文的文献
1
Stroke risk evaluation for patients with atrial fibrillation: Insights from left atrial appendage.
Front Cardiovasc Med. 2022 Aug 22;9:968630. doi: 10.3389/fcvm.2022.968630. eCollection 2022.
2
Non-pharmacological therapy for atrial fibrillation: managing the left atrial appendage.
Cardiol Res Pract. 2012;2012:304626. doi: 10.1155/2012/304626. Epub 2012 May 15.
本文引用的文献
1
2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Circulation. 2011 Mar 15;123(10):e269-367. doi: 10.1161/CIR.0b013e318214876d. Epub 2011 Mar 7.
2
Heart disease and stroke statistics--2011 update: a report from the American Heart Association.
Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15.
3
Feasibility of closed-chest ligation of the left atrial appendage in humans.
Heart Rhythm. 2011 Feb;8(2):188-93. doi: 10.1016/j.hrthm.2010.10.040. Epub 2010 Nov 2.
4
Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience.
Catheter Cardiovasc Interv. 2011 Apr 1;77(5):700-6. doi: 10.1002/ccd.22764. Epub 2011 Mar 8.
5
A novel approach to left atrial appendage exclusion: the WATCHMAN device.
Cardiol Rev. 2010 Sep-Oct;18(5):230-3. doi: 10.1097/CRD.0b013e3181e53abb.
6
Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model.
Circ Cardiovasc Interv. 2010 Jun 1;3(3):224-9. doi: 10.1161/CIRCINTERVENTIONS.109.914978. Epub 2010 May 18.
7
Dabigatran versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
8
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
Lancet. 2009 Aug 15;374(9689):534-42. doi: 10.1016/S0140-6736(09)61343-X.
9
INR variability in atrial fibrillation: a risk model for cerebrovascular events.
Eur J Intern Med. 2009 Jan;20(1):63-9. doi: 10.1016/j.ejim.2008.04.005. Epub 2008 Jun 25.
10
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited.
Lancet. 2009 Jan 10;373(9658):155-66. doi: 10.1016/S0140-6736(09)60040-4.
Zotero 插件